ABSTRACT
OBJECTIVE: Pediatric spondylodiscitis (PSD) is an uncommon condition, for which there are no specific international clinical guidelines. Factors related to complications have not been stablished. Our aim was to describe clinical and epidemiological characteristics of PSD, to analyze factors associated with complications and to evaluate adherence to the recommendations of the Spanish National Consensus Document (NCD) for the diagnostic and therapeutic approach to acute osteoarticular infections. MATERIAL AND METHODS: Ambispective, multicenter, national study of two PSD cohorts: historical (2008-2012) and prospective (2015-2020, after publication of NCD). Patients with diagnosis of PSD were included. Demographic, clinical, microbiological and radiological data were recorded. Factors related to the development of complications were analized by logistic regression. Comparisons between both cohorts were performed. RESULTS: Ninety-eight PSD were included. In 84.7%, diagnosis was confirmed by magnetic resonance imaging. Microbiological isolation was obtained in 6.1%, with methicillin-sensitive S. aureus as the main etiologic agent. Complications occurred in 18.9%, the most frequent being soft tissue abscess. Of the 8.6% of patients with sequelae, persistent pain was the most common. Comparing cohorts, there was better adherence to NCD treatment recommendations in the prospective one (57.6% vs. 12.9%, pâ¯<â¯0.01), including a reduction in the length of intravenous antibiotic therapy (10 vs. 14 days, pâ¯<â¯0.01). CONCLUSIONS: The evolution of PSD in our series was favorable, with low frequency of complications and sequelae. The adherence to the recommendations of the NCD was high. Studies with larger sample size are needed to establish new recommendations to optimize the approach to these infections.
ABSTRACT
In recent years, there has been a growing interest in developing portable and personal devices for measuring air quality and surrounding pollutants, partly due to the need for ventilation in the aftermath of COVID-19 situation. Moreover, the monitoring of hazardous chemical agents is a focus for ensuring compliance with safety standards and is an indispensable component in safeguarding human welfare. Air quality measurement is conducted by public institutions with high precision but costly equipment, which requires constant calibration and maintenance by highly qualified personnel for its proper operation. Such devices, used as reference stations, have a low spatial resolution since, due to their high cost, they are usually located in a few fixed places in the city or region to be studied. However, they also have a low temporal resolution, providing few samples per hour. To overcome these drawbacks and to provide people with personalized and up-to-date air quality information, a personal device (smartwatch) based on MEMS gas sensors has been developed. The methodology followed to validate the performance of the prototype was as follows: firstly, the detection capability was tested by measuring carbon dioxide and methane at different concentrations, resulting in low detection limits; secondly, several experiments were performed to test the discrimination capability against gases such as toluene, xylene, and ethylbenzene. principal component analysis of the data showed good separation and discrimination between the gases measured.
Subject(s)
COVID-19 , Carbon Dioxide , Environmental Monitoring , Environmental Monitoring/instrumentation , Environmental Monitoring/methods , Humans , Carbon Dioxide/analysis , Air Pollutants/analysis , Air Pollution/analysis , Gases/analysis , SARS-CoV-2/isolation & purification , Methane/analysisABSTRACT
Intravascular devices are essential for the diagnostic and therapeutic approach to multiple diseases in paediatrics, and central venous catheters (CVCs) are especially important. One of the most frequent complications is the infection of these devices, which is associated with a high morbidity and mortality. These infections are highly complex, requiring the use of substantial resources, both for their diagnosis and treatment, and affect vulnerable paediatric patients admitted to high-complexity units more frequently. There is less evidence on their management in paediatric patients compared to adults, and no consensus documents on the subject have been published in Spain. The objective of this document, developed jointly by the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Intensive Care (SECIP), is to provide consensus recommendations based on the greatest degree of evidence available to optimize the diagnosis and treatment of catheter-related bloodstream infections (CRBSIs). This document focuses on non-neonatal paediatric patients with CRBSIs and does not address the prevention of these infections.
Subject(s)
Catheter-Related Infections , Humans , Catheter-Related Infections/diagnosis , Catheter-Related Infections/prevention & control , Catheter-Related Infections/therapy , Child , Central Venous Catheters/adverse effects , Catheterization, Central Venous/adverse effects , SpainABSTRACT
OBJECTIVES: To describe the in vivo emergence of ceftazidime-avibactam resistance in GES-type carbapenemases and to characterize an unusual outbreak of GES-6-producing Serratia marcescens during the COVID-19 pandemic in Spain. METHODS: Retrospective study to describe a GES-CPSM outbreak based on whole genome sequencing and antimicrobial susceptibility testing (AST). Transferability of blaGES-carrying plasmid was assessed by conjugation experiments. RESULTS: In December 2020, we identified a cluster of S. marcescens harbouring blaGES-6 involving 9 patients. Whole-genome sequence analysis revealed a clonal relationship (≤3 SNPs) between the first isolates identified in each of the evolved patients and environmental samples with GES-CPSM detection. Plasmid analysis showed that the blaGES-6 gene was located in an IncQ3-type plasmid. Triparental mating experiments using a helper plasmid demonstrated mobilization of the blaGES-6-carrying plasmid. Our results also demonstrate within-host evolution in S. marcescens isolates, leading to a transition from blaGES-6 to the new blaGES-55, caused by the P162S mutation, in a subsequent infection in one of the affected patients. In blaGES-55 we identified emergence of ceftazidime-avibactam resistance along with an increase of carbapenems susceptibility. This patient had been treated with a 14-day course of ceftazidime-avibactam. AST of the transformants bearing blaGES-6 and blaGES-55 plasmids, confirmed susceptibility variation affecting ceftazidime-avibactam and carbapenems. CONCLUSIONS: We report an unusual outbreak of GES-6 whose incidence is becoming increasing. Transition from GES-6 to GES-55 may readily occur in vivo leading to ceftazidime-avibactam resistance, which brings to the fore the critical need for developing more accurate diagnosis tools for detection of GES ß-lactamases and optimise the use of antimicrobials.
Subject(s)
Anti-Bacterial Agents , Azabicyclo Compounds , Carbapenems , Ceftazidime , Disease Outbreaks , Drug Combinations , Microbial Sensitivity Tests , Serratia Infections , Serratia marcescens , beta-Lactamases , Humans , Ceftazidime/pharmacology , Serratia marcescens/genetics , Serratia marcescens/drug effects , Serratia marcescens/isolation & purification , Azabicyclo Compounds/pharmacology , Serratia Infections/microbiology , Serratia Infections/epidemiology , beta-Lactamases/genetics , beta-Lactamases/metabolism , Retrospective Studies , Carbapenems/pharmacology , Male , Anti-Bacterial Agents/pharmacology , Female , Middle Aged , Plasmids/genetics , Spain/epidemiology , COVID-19/epidemiology , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Whole Genome Sequencing , Aged , Drug Resistance, Multiple, Bacterial/geneticsABSTRACT
Herein, we combined different bioinformatics tools and databases (BV-BRC, ResFinder, RAST, and KmerResistance) to perform a prediction of antimicrobial resistance (AMR) in the genomic sequences of 107 Corynebacterium striatum isolates for which trustable antimicrobial susceptibility (AST) phenotypes could be retrieved. Then, the reliabilities of the AMR predictions were evaluated by different metrics: area under the ROC curve (AUC); Major Error Rates (MERs) and Very Major Error Rates (VMERs); Matthews Correlation Coefficient (MCC); F1-Score; and Accuracy. Out of 15 genes that were reliably detected in the C. striatum isolates, only tetW yielded predictive values for tetracycline resistance that were acceptable considering Food and Drug Administration (FDA)'s criteria for quality (MER < 3.0% and VMER with a 95% C.I. ≤1.5-≤7.5); this was accompanied by a MCC score higher than 0.9 for this gene. Noteworthy, our results indicate that other commonly used metrics (AUC, F1-score, and Accuracy) may render overoptimistic evaluations of AMR-prediction reliabilities on imbalanced datasets. Accordingly, out of 10 genes tested by PCR on additional multidrug-resistant Corynebacterium spp. isolates (n = 18), the tetW gene rendered the best agreement values with AST profiles (94.11%). Overall, our results indicate that genome-based AMR prediction can still be challenging for MDR clinical isolates of emerging Corynebacterium spp.
ABSTRACT
Central nervous system infections in children caused by group A Streptococcus are rare. This study, conducted across 52 hospitals in Spain from 2019 to 2023, identified 32 cases of central nervous system infections in children caused by group A Streptococcus, with a significant increase from October 2022 onward (1.1% vs. 5.9%, P = 0.002). Half required pediatric intensive care unit admission, 12.5% exhibited sequelae and the mortality rate was 6.2%. Mastoiditis was the predominant primary infection.
ABSTRACT
OBJECTIVE: The objective of this study was to assess the role of T-lymphocyte immune responses in newborns with congenital cytomegalovirus (CMV) infection (cCMV) and their potential association with the development of long-term sequelae. STUDY DESIGN: A multicenter, prospective study from 2017 to 2022 was conducted across 8 hospitals in Spain. Blood samples were collected within the first month of life from neonates diagnosed with cCMV. Intracellular cytokine staining was employed to evaluate the presence of CMV-specific interferon-gamma (IFN-γ)-producing CD8+ and CD4+ T lymphocytes (CMV-IFN-γ-CD8+/CD4+) using flow cytometry. The development of sequelae, including hearing loss and neurologic impairment, was assessed during follow-up. RESULTS: In total, 64 newborns were included; 42 infants (65.6%) had symptomatic cCMV. The median age at the last follow-up visit was 25.3 months (IQR 20.1-34.4). Eighteen infants had long-term sequelae (28.1%), predominantly hearing loss (20.3%) and neurologic disorders (15.6%). No relationship was observed between total count or percentage of CMV-specific IFN-γ-CD8+ or CD4+ lymphocytes and long-term sequelae. Multivariable analysis demonstrated an association between lower total lymphocyte count and long-term sequelae (aOR 0.549, 95% CI: 0.323-0.833), which requires further study. CONCLUSIONS: CMV-specific IFN-γ-CD4+ and CD8+ T-lymphocyte responses in neonates with cCMV were not predictive of long-term sequelae.
ABSTRACT
We analyzed 136 children with tuberculosis disease or infection and a positive QuantiFERON-TB (QFT) assay, followed-up for a median of 21 months (0.4-11years). QFT reversed in 16.9% of cases, with significant decreases in TB1 (-1.72 vs. -0.03 IU/ml, p=0.001) and TB2 (-1.65 vs. -0.43 IU/ml, p=0.005) levels compared to non-reverters. We found a higher QFT reversion rate among children under 5 years (25.0% vs 11.9%, p=0.042), and those with TST induration <15mm (29% vs 13.3%, p=0.055). Our data reveal that, although QFT test remained positive in the majority of children, reversion occurred in 16% of cases in a progressive and stable pattern. Younger age and reduced TST induration were associated with QFT reversion.
Subject(s)
Tuberculin Test , Tuberculosis , Child , Humans , Adolescent , Child, Preschool , Tuberculosis/diagnosisSubject(s)
Humans , Male , Female , Child , Adolescent , Pediatrics , Streptococcus pyogenes , Incidence , EpidemiologyABSTRACT
Antecedentes: La enfermedad pulmonar obstructiva crónica (EPOC) produce una obstrucción al flujo de aire de los pulmones que genera tos, mucosidad y dificultad respiratoria. Presenta una alta morbimortalidad y tiene una prevalencia del 10,3% en todo el mundo. Recientemente se ha sugerido el uso del entrenamiento diafragmático en estos pacientes. Objetivo: El objetivo fue examinar la evidencia disponible sobre la eficacia del entrenamiento del diafragma sobre el FEV1, la prueba de la marcha de 6 minutos, la saturación de oxígeno, el tiempo inspiratorio, el tiempo espiratorio y la escala de supervivencia de la EPOC (BODE). Material y métodos: Se realizó una revisión sistemática siguiendo la declaración PRISMA. Resultados: Los resultados mostraron que el entrenamiento del diafragma es efectivo en pacientes con EPOC para mejorar el FEV1. Conclusiones: La prueba de la marcha de 6 minutos y la saturación de oxígeno; sin embargo, no es efectivo para las variables tiempo inspiratorio, tiempo espiratorio y escala de supervivencia de la EPOC (BODE). (AU)
Background: Chronic obstructive pulmonary disease (COPD) causes an obstruction to the airflow of the lungs, causing coughing, mucus, and difficulty breathing. It has a high morbidity and mortality with a prevalence of 10.3% worldwide. The use of diaphragmatic training in these patients has recently been suggested. Objective: The objective was to examine the available evidence on the effectiveness of diaphragm training on FEV1, 6-minute walk test, oxygen saturation, inspiratory time, expiratory time and COPD survival scale (BODE). Material and methods: A systematic review was carried out following the PRISMA regulations. Results: The results showed that diaphragm training is effective in patients with chronic obstructive pulmonary disease to improve FEV1. Conclusion: 6-minute walk test and oxygen saturation; however, it is not effective for the variables inspiratory time, expiratory time and the COPD survival scale (BODE). (AU)
Subject(s)
Humans , Pulmonary Disease, Chronic Obstructive , Diaphragm , Breathing Exercises , Cough , Emphysema , Bronchitis, ChronicABSTRACT
Introducción y objetivo: La rinitis alérgica es una enfermedad inflamatoria crónica de la mucosa nasal, mediada por inmunoglobulina E. Afecta a uno de cada seis individuos, con una prevalencia del 10% al 40 % en la población. En los últimos años se ha propuesto el uso de la rinofototerapia para reducir sus síntomas en pacientes que no pueden beneficiarse de los corticosteroides intranasales o los antihistamínicos orales; así como tratamiento adyuvante a los mismos. El objetivo de esta revisión es analizar la eficacia de la rinofototerapia como tratamiento adyuvante en la rinitis alérgica. Método: Se realizó una revisión siguiendo las directrices PRISMA. Se consultaron las bases de datos de PubMed, Cinahl, PsycINFO, SPORTDiscus, Academic Search Complete, Lilacs, IBECS, CENTRAL, SciELO, y WOS. Se utilizó la herramienta Cochrane para valorar el riesgo de sesgo y la calidad de la evidencia se evaluó GRADE. Resultados: La rinofototerapia es un tratamiento adyuvante eficaz en la rinitis alérgica. La muestra total fue de 251 pacientes. En todos los estudios fue segura la aplicación de rinofototerapia y la duración del tratamiento osciló entre dos y seis semanas, con una media de tres veces por semana. Discusión: En el futuro sería necesario continuar investigando para establecer un protocolo unificado en cuanto a la frecuencia, duración y número de sesiones. Así como analizar el posible efecto sinérgico de este tratamiento con otras terapias. Conclusiones: La rinofototerapia fue eficaz en pacientes con rinitis alérgica. Esta terapia mejora los síntomas clínicos de estornudos, rinorrea, obstrucción nasal, prurito nasal, prurito de paladar, las mediciones del flujo máximo inspiratorio nasal, la calidad de vida del paciente y la severidad de los síntomas. (AU)
Introduction and objective: Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa, mediated by immunoglobulin E. It affects one in six individuals, with a prevalence of 10% to 40% in the population. In recent years, the use of rhinophototherapy has been proposed to reduce its symptoms in patients who cannot benefit from intranasal corticosteroids or oral antihistamines; as well as adjuvant treatment to them. The objective of this review is to analyze the efficacy of rhinophototherapy as adjuvant treatment in allergic rhinitis. Method: A review was performed following PRISMA guidelines. The PubMed, Cinahl, PsycINFO, SPORTDiscus, Academic Search Complete, Lilacs, IBECS, CENTRAL, SciELO, and WOS databases were consulted. The Cochrane tool was used to assess the risk of bias and the quality of the evidence was assessed GRADE. Results: Rhinophototherapy is an effective adjuvant treatment in allergic rhinitis. The total sample was 251 patients. In all studies, the application of rhinophototherapy was safe and the duration of treatment ranged from two to six weeks, with an average of three times per week. Discussion: In the future it would be necessary to continue researching to establish a unified protocol regarding the frequency, duration and number of sessions. As well as analyzing the possible synergistic effect of this treatment with other therapies. Conclusions: Rhinophototherapy was effective in patients with allergic rhinitis. This therapy improves clinical symptoms of sneezing, rhinorrhea, nasal obstruction, nasal itching, palate itching, nasal inspiratory peak flow measurements, patient quality of life, and symptom severity. (AU)
Subject(s)
Humans , Rhinitis, Allergic/therapy , Phototherapy/methods , Phototherapy/trendsABSTRACT
In December 2022, an alert was published in the UK and other European countries reporting an unusual increase in the incidence of Streptococcus pyogenes infections. Our aim was to describe the clinical, microbiological, and molecular characteristics of group A Streptococcus invasive infections (iGAS) in children prospectively recruited in Spain (September 2022-March 2023), and compare invasive strains with strains causing mild infections. One hundred thirty isolates of S. pyogenes causing infection (102 iGAS and 28 mild infections) were included in the microbiological study: emm typing, antimicrobial susceptibility testing, and sequencing for core genome multilocus sequence typing (cgMLST), resistome, and virulome analysis. Clinical data were available from 93 cases and 21 controls. Pneumonia was the most frequent clinical syndrome (41/93; 44.1%), followed by deep tissue abscesses (23/93; 24.7%), and osteoarticular infections (11/93; 11.8%). Forty-six of 93 cases (49.5%) required admission to the pediatric intensive care unit. iGAS isolates mainly belonged to emm1 and emm12; emm12 predominated in 2022 but was surpassed by emm1 in 2023. Spread of M1UK sublineage (28/64 M1 isolates) was communicated for the first time in Spain, but it did not replace the still predominant sublineage M1global (36/64). Furthermore, a difference in emm types compared with the mild cases was observed with predominance of emm1, but also important representativeness of emm12 and emm89 isolates. Pneumonia, the most frequent and severe iGAS diagnosed, was associated with the speA gene, while the ssa superantigen was associated with milder cases. iGAS isolates were mainly susceptible to antimicrobials. cgMLST showed five major clusters: ST28-ST1357/emm1, ST36-ST425/emm12, ST242/emm12.37, ST39/emm4, and ST101-ST1295/emm89 isolates. IMPORTANCE: Group A Streptococcus (GAS) is a common bacterial pathogen in the pediatric population. In the last months of 2022, an unusual increase in GAS infections was detected in various countries. Certain strains were overrepresented, although the cause of this raise is not clear. In Spain, a significant increase in mild and severe cases was also observed; this study evaluates the clinical characteristics and the strains involved in both scenarios. Our study showed that the increase in incidence did not correlate with an increase in resistance or with an emm types shift. However, there seemed to be a rise in severity, partly related to a greater rate of pneumonia cases. These findings suggest a general increase in iGAS that highlights the need for surveillance. The introduction of whole genome sequencing in the diagnosis and surveillance of iGAS may improve the understanding of antibiotic resistance, virulence, and clones, facilitating its control and personalized treatment.
Subject(s)
Pneumonia , Streptococcal Infections , Child , Humans , Streptococcus pyogenes , Spain/epidemiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Antigens, Bacterial/genetics , Bacterial Outer Membrane Proteins/genetics , Streptococcal Infections/epidemiology , Streptococcal Infections/microbiologyABSTRACT
Infection of a native joint, commonly referred to as septic arthritis, is a medical emergency because of the risk of joint destruction and subsequent sequelae. Its diagnosis requires a high level of suspicion. These guidelines for the diagnosis and treatment of septic arthritis in children and adults are intended for use by any physician caring for patients with suspected or confirmed septic arthritis. They have been developed by a multidisciplinary panel with representatives from the Bone and Joint Infections Study Group (GEIO) belonging to the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Paediatric Infections (SEIP) and the Spanish Society of Orthopaedic Surgery and Traumatology (SECOT), and two rheumatologists. The recommendations are based on evidence derived from a systematic literature review and, failing that, on the opinion of the experts who prepared these guidelines. A detailed description of the background, methods, summary of evidence, the rationale supporting each recommendation, and gaps in knowledge can be found online in the complete document.
Subject(s)
Arthritis, Infectious , Adult , Humans , Child , Arthritis, Infectious/therapy , Arthritis, Infectious/drug therapy , Disease Progression , Anti-Bacterial Agents/therapeutic useABSTRACT
Viruses comprise the most abundant genetic material in the biosphere; however, global viral genomic population (virome) has been largely underestimated. Recently, high-throughput sequencing (HTS) has provided a powerful tool for the detection of known viruses and the discovery of novel viral species from environmental and individual samples using metagenomics and ecogenomics approaches, respectively. Viruses with circular DNA single-stranded (ssDNA) genomes belonging to the begomovirus genera (family Geminiviridae) constitute the largest group of emerging plant viruses worldwide. The knowledge of begomoviruses viromes is mostly restricted to crop plant systems; nevertheless, it has been described that noncultivated plants specifically at the interface between wild and cultivated plants are important reservoirs leading to viral evolution and the emergence of new diseases. Here we present a protocol that allows the identification and isolation of known and novel begomoviruses species infecting cultivated and noncultivated plant species. The method consists of circular viral molecules enrichment by rolling circle amplification (RCA) from begomovirus-positive total plant DNA, followed by NGS-based metagenomic sequencing. Subsequently, metagenomic reads are processed for taxonomic classification using Viromescan software and a customized Geminiviridae family database, and begomovirus-related reads are used for contigs assembly and annotation using Spades software and Blastn algorithm, respectively. Then, the obtained begomovirus-related signatures are used as templates for specific primers design and implemented for PCR-based ecogenomic identification of individual samples harboring the corresponding viral species. Lastly, full-length begomovirus genomes are obtained by RCA-based amplification from total plant DNA of selected individual samples, cloning, and viral molecular identity corroborated by Sanger sequencing. Conclusively, the identification and isolation of a novel monopartite begomovirus species native to the New World (NW) named Gallium leaf deformation virus (GLDV) is shown.
Subject(s)
Begomovirus , DNA, Viral , DNA, Viral/genetics , Phylogeny , Plants/genetics , Begomovirus/genetics , Genome, Viral , Metagenomics/methods , DNA, Plant , DNA, Circular/genetics , Plant DiseasesABSTRACT
Candida haemulonii complex (Candida haemulonii [I], Candida duobushaemulonii [II], and Candida haemulonii var. vulnera [III]) has become relevant in recent times, not so much because of a high incidence in human clinical sample cultures but because of its remarkable antifungal resistance. The objective of this study was to evaluate several methods for the identification of this uncommon species of Candida. Ten isolates of C. haemulonii were identified by biochemical and proteomic methods, and their antifungal susceptibility testing was performed by both commercial and reference methods. MALDI-TOF MS (Vitek MS and Vitek MS PRIME) and Vitek2 correctly identified these genera but API method did not. There was a good correlation between the commercial methods and the reference methods for the AST. In conclusion Vitek MS, Vitek MS PRIME, and Vitek2 systems, but not API32C, are reliable for identification of C. haemulonii complex. Furthermore, MALDI-TOF MS systems could identify to the subspecies level. Commercial methods for antifungal susceptibility testing are valid for the study of this species and confirm amphotericin B and to azole resistance.
Subject(s)
Antifungal Agents , Saccharomycetales , Humans , Antifungal Agents/pharmacology , Proteomics , Candida , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methodsABSTRACT
Introducción: La esclerosis múltiple es una enfermedad autoinmune desmielinizante y neurodegenerativa. Actualmente hay 2.800.000 personas con esclerosis múltiple, suponiendo la enfermedad discapacitante no traumática más común que afecta a los adultos jóvenes. En los últimos años se ha propuesto el uso de la hipoterapia en estos pacientes. La hipoterapia utiliza el movimiento del caballo para proporcionar retroalimentación sensorial. El objetivo de este trabajo es realizar una revisión de la literatura sobre la eficacia de la hipoterapia en pacientes con esclerosis múltiple. Método: Se realizó una revisión siguiendo la normativa PRISMA. Se consultaron las bases de datos de PubMed, Cinahl, PsycINFO, SPORTDiscus, Academic Search Complete, Lilacs, IBECS, CENTRAL, SciELO, y WOS. Se utilizó la herramienta Cochrane para valorar el riesgo de sesgo y la calidad de la evidencia se evaluó GRADE Resultados: La hipoterapia es eficaz en pacientes con esclerosis múltiple. La muestra fue de 179 pacientes de un total de seis estudios. El número total de sesiones osciló entre 10 y 36, con una frecuencia de una o dos veces por semana, 30 minutos sesión y una duración total de la terapia entre 8 y 24 semanas Conclusiones: La hipoterapia mejora el equilibrio, las actividades de la vida diaria, la movilidad, la fatiga, la espasticidad, la fuerza muscular y la calidad de vida en pacientes con esclerosis múltiple. (AU)
Subject(s)
Humans , Equine-Assisted Therapy , Multiple Sclerosis , Therapeutics , Autoimmune Diseases , Demyelinating Diseases , Neurodegenerative DiseasesABSTRACT
La enfermedad pulmonar obstructiva crónica (EPOC) provoca tos, disnea y falta de energía, y es la tercera causa de muerte en todo el mundo. El entrenamiento del diafragma se muestra como una opción útil y poco agresiva en estos pacientes. El objetivo fue analizar la evidencia existente acerca de los efectos del entrenamiento del diafragma sobre la disnea en pacientes con EPOC. Se realizó una revisión sistemática siguiendo la declaración PRISMA. Se consultaron las bases de datos PubMed, Cinahl, PsycINFO, SPORTDiscus, Academic Search Complete, Lilacs, IBECS, CENTRAL, SciELO y WOS. Se seleccionaron ensayos clínicos controlados aleatorizados centrados en el efecto del entrenamiento del diafragma sobre la disnea en pacientes con EPOC. Se utilizó la herramienta propuesta por Cochrane para la valoración del riesgo de sesgo, y la calidad de la evidencia se valoró con el sistema GRADE. Se seleccionaron tres ensayos clínicos controlados aleatorizados (n = 88; rango-edad: 60-69 años) considerados de bajo riesgo de sesgo. Se concluye que el entrenamiento del diafragma no es una terapia efectiva para mejorar la disnea. (AU)
Chronic obstructive pulmonary disease (COPD) causes cough, dyspnea, and lack of energy, being the third cause of death worldwide. Diaphragm training appears to be a useful and non-aggressive treatment in these patients. The objective was to analyze the existing evidence on the effects of diaphragm training on dyspnea in patients with COPD. A systematic review was carried out following the PRISMA statement. The PubMed, Cinahl, PsycINFO, SPORTDiscus, Academic Search Complete, Lilacs, IBECS, CENTRAL, SciELO, and WOS databases were searched. Randomized controlled clinical trials focusing on the effect of diaphragm training on breathlessness in patients with COPD were selected. The tool proposed by Cochrane was used for the assessment of risk of bias and the quality of evidence was assessed using the GRADE system. Three randomized controlled clinical trials (n = 88; age range: 6069 years) considered to be of low risk of bias were selected. Diaphragm training is not an effective therapy to treat dyspnea. (AU)
Subject(s)
Humans , Pulmonary Disease, Chronic Obstructive , Dyspnea , Breathing Exercises/adverse effects , Diaphragm , Breathing Exercises/methodsABSTRACT
Antiphospholipid syndrome (APS) is a thromboinflammatory disorder caused by circulating antiphospholipid autoantibodies (aPL) and characterized by an increased risk of thrombotic events. The pathogenic mechanisms of these antibodies are complex and not fully understood, but disturbances in coagulation and fibrinolysis have been proposed to contribute to the thrombophilic state. This study aims to evaluate the role of an emerging hemostatic molecule, FXI, in the thrombotic risk of patients with aPL. Cross-sectional and observational study of 194 consecutive and unrelated cases with aPL recruited in a single center: 82 asymptomatic (AaPL) and 112 with primary antiphospholipid syndrome (APS). Clinical and epidemiological variables were collected. The profile of aPL was determined. Plasma FXI was evaluated by Western blotting and two coagulation assays (FXI:C). In cases with low FXI, molecular analysis of the F11 gene was performed. FXI:C levels were significantly higher in patients with APS than in patients with AaPL (122.8 ± 33.4 vs. 104.5 ± 27.5; p < 0.001). Multivariate analysis showed a significant association between symptomatic patients with aPL (APS) and high FXI (>150%) (OR = 11.57; 95% CI: 1.47-90.96; p = 0.020). In contrast, low FXI (<70%), mostly caused by inhibitors, was less frequent in the group of patients with APS compared to AaPL (OR = 0.17; 95%CI: 0.36-0.86; p = 0.032). This study suggests that FXI levels may play a causal role in the prothrombotic state induced by aPLs and holds the promise of complementary treatments in APS patients by targeting FXI.